SCHEMBL9965450

SCHEMBL9965450

CC(=O)N1CCC(C(=O)Nc2ccccc2-c2ccccc2)CC1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.68
TP53 P04637 1/20 0.60
ALOX15 P16050 1/20 0.60
MAPK1 P28482 1/20 0.60
CASP1 P29466 1/20 0.60
CASP7 P55210 1/20 0.60
HSD17B10 Q99714 1/20 0.60
MAPK8 P45983 1/20 0.55
MAPK10 P53779 1/20 0.55
TSHR P16473 2/20 0.54
KDM4E B2RXH2 1/20 0.54
HDAC3 O15379 3/20 0.53
HDAC1 Q13547 3/20 0.53
HDAC2 Q92769 3/20 0.53
PTPN1 P18031 1/20 0.53
CYP3A4 P08684 1/20 0.52
CYP2D6 P10635 1/20 0.52
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52
ACHE P22303 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL38659461 0.82 ALDH1A1 (0.94) ALDH1A1HSD17B10TSHRKDM4EHDAC3
SCHEMBL9965473 0.81 TSHR (0.54) ALDH1A1TP53ALOX15MAPK1CASP1
SCHEMBL9965417 0.81 EPHX2 (0.57) TP53ALOX15MAPK1CASP1CASP7
SCHEMBL2892697 0.81 KDM4E (0.55) ALDH1A1TP53ALOX15MAPK1CASP1
SCHEMBL13735120 0.81 HDAC1 (0.65) TP53ALOX15MAPK1CASP1CASP7
SCHEMBL17532983 0.79 TP53 (0.57) ALDH1A1TP53ALOX15MAPK1CASP1
SCHEMBL18658132 0.77 MAPT (0.57) ALDH1A1HDAC3HDAC1HDAC2MEN1
SCHEMBL26131114 0.77 ALDH1A1 (0.54) ALDH1A1TP53ALOX15MAPK1CASP1
SCHEMBL9059796 0.75 ALDH1A1 (0.50) ALDH1A1TSHRCYP3A4CYP2D6CYP2C9
SCHEMBL1502589 0.73 PTPN2 (0.55) ALDH1A1KDM4EPTPN1ACHEBACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1960347-B1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 (17BETA-HSD3) INHIBITORS STERIX LTD (GB) 2012-06-20 EP disclosed
US-8119627-B2 Heterocyclic compounds as inhibitors of 17beta-HSD3 STERIX LIMITED (GB) 2012-02-21 US disclosed
US-8119627-B2 Heterocyclic compounds as inhibitors of 17beta-HSD3 STERIX LIMITED (GB) 2012-02-21 US disclosed
US-20090023710-A1 Compound OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2009-01-22 US disclosed
US-20090023710-A1 Compound OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2009-01-22 US disclosed
WO-2007003934-A2 17BETA-HYDR0XYSTER0ID DEHYDROGENASE TYPE 3 (17BETA-HSD3 ) INHIBITORS STERIX LIMITED (GB) 2007-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023710-A1 Compound NR1H3, NR1H2, NR1H4 ALDH1A1 2109/4885TP53 4466/4885ALOX15 1275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.